If you have hypertrophic cardiomyopathy (HCM) and are experiencing symptoms such as shortness of breath, chest pain, ...
The Global Ventricular Tachycardia Market is estimated to be valued at USD 15.52 Bn in 2025 and is expected to reach USD 22.28 Bn by 2032, reflecting a compound annual growth rate (CAGR) of 5.3% from ...
A faulty ion channel function is a consistent biological feature of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome ...
A new study published in the Journal of American Medical Association showed that Ethosuximide was linked to decreased ...
Ethosuximide does not demonstrate efficacy over placebo for the treatment of irritable bowel syndrome-related abdominal pain and has limited tolerability.
Novamigra Therapeutics secures ~€3 million funding to advance first-in-human Phase 1 study of its migraine prophylaxis ...
Woman's World on MSN
Is your BP pill making you tired? This MD shares what to avoid
"The main side effect is them not working! Not everyone responds to every drug." The common blood pressure drug you may want ...
44.7 percent of angiotensin receptor blocker initiators were continuously persistent to original drug class at three years.
Milestone Pharmaceuticals (MIST) announced the acceptance of a Marketing Authorization Application, MAA, by the European Medicines Agency, EMA, seeking the approval of etripamil nasal spray, developed ...
European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective self-administered treatment option for PSVT outside of the ...
SaveHealth reports on 10 hypertension medications, their classifications, effectiveness, side effects, and safety in managing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback